Healthcare resource use by PSVT patients undergoing cardiac ablation
HEORStrategies’ Dr. Naomi Sacks is a co-author on a study of healthcare resource use and costs in cardiac arrhythmia patients with paroxysmal supraventricular… read more
Latest News
EpidStrategies Supports Neuralace Medical Submission for FDA Approval of Axon Therapy
Neuralace Medical recently received FDA clearance of Axon Therapy for diabetic patients suffering from chronic painful neuropathy. The EpidStrategies medical device trials team… read more
HEORStrategies’ Dr. Naomi Sacks is a Co-Author on a Study of Trends in Myasthenia Gravis Hospitalizations and Mortality
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study on myasthenia gravis (MG) just published in the journal Neurology. MG… read more
HEORStrategies’ Dr. Naomi Sacks is a co-author on a large-scale study of obesity and overweight in the United States
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study just published in the journal Obesity Science and Practice. Using national… read more
Announcing HEORStrategies, the newest division of ToxStrategies LLC!
HEORStrategies provides robust, strategic health economics and outcomes research (HEOR) consulting services to pharma, biotech, and medical device clients!
EpidStrategies’ Scientists are Presenting on RSV at IDWeek 2023
EpidStrategies’ scientists are recognized experts in the field of respiratory syncytial virus (RSV). Our RSV research program supported the newly-approved monoclonal antibody with… read more
Dr. Michael Kelsh joins EpidStrategies, a Division of ToxStrategies LLC
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
New Infant RSV Prevention to be Available this Fall
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more